Long-term outcomes and left ventricular diastolic function of sarcomere mutation-positive and mutation-negative patients with hypertrophic cardiomyopathy: a prospective cohort study

• Published in: European heart journal cardiovascular imaging
• Main Authors: Chen, Ching-Yu Julius, Su, Mao-Yuan Marine, Liao, Ying-Chieh, Chang, Fu-Lan, Wu, Cho-Kai, Lin, Lian-Yu, Chen, Yih-Shurng, Lin, Yen-Hung, Hwang, Juey-Jen, Yu, Sung-Liang, Kao, Hsien-Li, Chen, Wen-Jone, Lu, Tzu-Pin, Shih, Ching-Yu, Yeh, Shih-Fan Sherri, Yang, Dun-Hui, Lai, Ling-Ping, Juang, Jyh-Ming Jimmy
• Format: Journal Article
• Language: English
• Published: England 22.11.2020
• Subjects: cardiac diastolic dysfunction; global longitudinal strain; sarcomere mutation; hypertrophic cardiomyopathy
• ISSN: 2047-2412
• DOI: 10.1093/ehjci/jeaa317

Hypertrophic cardiomyopathy (HCM) is an inheritable disease that leads to sudden cardiac death and heart failure (HF). Sarcomere mutations (SMs) have been associated with HF. However, the differences in ventricular function between SM-positive and SM-negative HCM patients are poorly characterized. Of the prospectively enrolled 374 unrelated HCM patients in Taiwan, 115 patients underwent both 91 cardiomyopathy-related gene screening and cardiovascular magnetic resonance (45.6 ± 10.6 years old, 76.5% were male). Forty pathogenic/likely pathogenic mutations were identified in 52 patients by next-generation sequencing. The SM-positive group were younger at first cardiovascular event (P = 0.04) and progression to diastolic HF (P = 0.02) with higher N-terminal pro-brain natriuretic peptide (NT-proBNP) [New York Heart Association (NYHA) Class III/IV symptoms with left ventricular ejection fraction > 55%] than the SM-negative group (P < 0.001). SM-positive patients had a greater extent of late gadolinium enhancement (P = 0.01), larger left atrial diameter (P = 0.03), higher normalized peak filling rate (PFR) and PFR ratio, and a greater reduction in global longitudinal strain than SM-negative patients (all P ≤ 0.01). During mean lifelong follow-up time (49.2 ± 15.6 years), SM-positive was a predictor of earlier HF (NYHA Class III/IV symptoms) after multivariate adjustment (hazard ratio 3.5; 95% confidence interval 1.3-9.7; P = 0.015). SM-positive HCM patients had a higher extent of myocardial fibrosis and more severe ventricular diastolic dysfunction than those without, which may contribute to earlier onset of advanced HF, suggesting the importance of close surveillance and early treatment throughout life.